Scientific World Model

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Showing 1–50 of 821 pages matching "ALS"

Clinical TrialsKG

index · 1,719 words · 102 hyp23 ana55 exp

🏥 Progressive Supranuclear Palsy (PSP)KG

disease · 12,907 words · 29 hyp8 ana63 exp

nimodipine-alsKG

clinical_trial · 5,778 words · 189 hyp30 ana37 exp

🧪 PI-2620 Tau PET in PSPKG

clinical · 5,625 words · 4 hyp3 ana7 exp

nct07165106KG

clinical_trial · 5,178 words · 19 hyp4 ana7 exp

⚙️ ALS Failed Approaches AnalysisKG

mechanism · 4,973 words · 8 hyp58 ana58 exp

💊 CBS/PSP Clinical Trials GuideKG

therapeutic · 4,969 words · 17 hyp5 ana53 exp

🧪 DIAN-TU-001 Trial (NCT01760005)KG

clinical · 4,560 words · 10 hyp5 ana8 exp

🧪 Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Lateral SclerosisKG

clinical · 4,511 words · 71 hyp51 ana26 exp

🧪 Lithium for PSP/CBS — Phase 2 TrialKG

clinical · 4,474 words · 25 hyp10 ana12 exp

dimethyl-fumarate-nrf2-ad-nct06850597KG

clinical_trial · 4,373 words · 8 hyp2 ana11 exp

⚙️ Epigenetic Dysregulation Comparison -- AD/PD/ALS/FTD/HDKG

mechanism · 4,361 words · 54 hyp46 ana46 exp

⚙️ Pre-symptomatic Conversion Windows in ALS Genetic Risk CarriersKG

mechanism · 4,322 words · 29 hyp51 ana27 exp

🧪 A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseaseKG

clinical · 4,279 words · 69 hyp33 ana52 exp

🧪 PMN310 Anti-Amyloid for AD (NCT06750432)KG

clinical · 4,244 words · 51 hyp22 ana15 exp

🧪 Clinical Trials DashboardKG

clinical · 4,199 words · 17 hyp35 ana24 exp

🧪 FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)KG

clinical · 4,197 words · 10 hyp14 ana3 exp

🧪 Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)KG

clinical · 4,079 words · 71 hyp28 ana65 exp

🧪 KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)KG

clinical · 3,985 words · 43 hyp17 ana50 exp

🧪 Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)KG

clinical · 3,941 words · 84 hyp24 ana56 exp

🏢 Idorsia Pharmaceuticals Ltd.

company · 3,906 words · 9 hyp5 ana35 exp

⚙️ Lipid Metabolism Dysfunction Comparison — AD/PD/ALS/FTD/HDKG

mechanism · 3,831 words · 45 hyp41 ana46 exp

🧪 Genistein for Mild Cognitive Impairment (NCT07385937)KG

clinical · 3,822 words · 22 hyp2 ana3 exp

⚙️ Autophagy-Lysosomal Impairment Comparison — AD/PD/ALS/FTD/HDKG

mechanism · 3,688 words · 38 hyp37 ana45 exp

🧪 E2814 — Phase 2 for 4R-TauopathyKG

clinical · 3,678 words · 14 hyp5 ana4 exp

⚙️ Neuroinflammation Across AD, PD, ALS, FTD, and HDKG

mechanism · 3,668 words · 54 hyp54 ana47 exp

🧪 Rotigotine and Rivastigmine Combination Therapy for Alzheimer's Disease (NCT06702124)KG

clinical · 3,657 words · 59 hyp35 ana50 exp

⚙️ Disease Progression and Staging in Progressive Supranuclear PalsyKG

mechanism · 3,633 words · 15 hyp44 ana26 exp

🧪 BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's DiseaseKG

clinical · 3,627 words · 41 hyp22 ana64 exp

🏥 ALS-FTD SpectrumKG

disease · 3,586 words · 20 hyp22 ana63 exp

🧪 FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear PalsyKG

clinical · 3,559 words · 17 hyp7 ana26 exp

⚙️ Neuroinflammation in Amyotrophic Lateral SclerosisKG

mechanism · 3,509 words · 30 hyp54 ana16 exp

⚙️ Mitochondrial Dysfunction in Progressive Supranuclear PalsyKG

mechanism · 3,494 words · 47 hyp45 ana29 exp

amiloride-alsKG

clinical_trial · 3,477 words · 182 hyp24 ana50 exp

⚙️ TDP-43 Proteinopathy in Amyotrophic Lateral SclerosisKG

mechanism · 3,471 words · 18 hyp59 ana33 exp

🏥 Amyotrophic Lateral Sclerosis (ALS)KG

disease · 3,458 words · 119 hyp28 ana65 exp

🧪 Portable Driving Simulator for PD Assessment (NCT03969927)KG

clinical · 3,450 words · 2 hyp13 ana6 exp

⚙️ Autophagy Failure Comparison -- AD/PD/ALS/FTD/HDKG

mechanism · 3,424 words · 18 hyp39 ana37 exp

🧪 KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD AgitationKG

clinical · 3,402 words · 16 hyp6 ana1 exp

🧪 A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)KG

clinical · 3,383 words · 9 hyp6 ana2 exp

🧪 Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)KG

clinical · 3,330 words · 10 hyp15 ana59 exp

Progressive Supranuclear Palsy (PSP) PathwayKG

mechanisms · 3,322 words · 16 hyp39 ana29 exp

🏥 Progressive Supranuclear PalsyKG

disease · 3,312 words · 19 hyp11 ana57 exp

al002-trem2-agonist-alzheimersKG

clinical_trial · 3,309 words · 52 hyp27 ana9 exp

🧪 Methylphenidate + iTBS for Apathy in AD (PRIME Trial)KG

clinical · 3,302 words · 49 hyp9 ana18 exp

nct07322003KG

clinical_trial · 3,292 words · 7 hyp1 ana6 exp

🧪 CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in ADKG

clinical · 3,284 words · 31 hyp9 ana4 exp

nct06365190-rtms-pdKG

clinical_trial · 3,270 words · 18 hyp3 ana16 exp

🧪 Riluzole ALS TrialsKG

clinical · 3,263 words · 186 hyp28 ana42 exp

🏢 ALS PipelineKG

company · 3,225 words · 13 hyp20 ana56 exp